Dr. Mohana Rao Patibandla (Dr. Rao) Recognized By The Times Of India For Transforming Neurosurgical Care In India
(MENAFN - EIN Presswire)Dr. Mohana Rao Patibandla receives the–Best Minimally Invasive Neurosurgeon, Spine Surgeon, and Endovascular Surgeon in India 2025– award from the Chief Minister of Goa, Dr. ...
Oxford Brain Diagnostics Rolls Out CDM® for Dementia Detection
Oxford Brain Diagnostics (OBD) is set to revolutionize brain health assessment with its patented Cortical Disarray Measurement (CDM®) technology. With over 55 million people worldwide affected by dementia—a number expected to nearly double every two decades—OBD’s CDM® offers a critical, data-driven solution. By analyzing standard MRI scans, the software delivers a quantifiable measure of neurodegeneration, supporting earlier and more accurate diagnoses. Having secured FDA 510(k) clearance and UKCA self-certification, Oxford Brain Diagnostics is now launching its commercial rollout across the UK and US, bringing cutting-edge brain health insights to healthcare providers and patients on a global scale. Founded in 2019 by Dr Steven Chance (former Associate Professor of Neuroscience at Oxford University) and Professor Mark Jenkinson (Professor of Neuroimaging), Oxford Brain Diagnostics has built its technology on decades of expertise in brain pathology and imaging. The FDA recognised CDM’s potential in 2020 by granting Breakthrough Device Designation status for evaluating adults at risk of Alzheimer’s Disease. In 2023 OBD secured a multi-million investment in a funding round led by BGF, the UK and Ireland’s most active growth capital investor, alongside continued support from its existing investors, including the Oxford Technology & Innovations Fund (OTIF). This crucial investment enabled OBD to ...
Book Reviews
What’s good, what’s bad, and what’s in between in literature this year? Here we review the latest titles.
INBRIJA Positioned For Stronger Market Penetration As Demand Grows For Inhaled Parkinson's Therapy Delveinsight
(MENAFN - PR Newswire) INBRIJA, a dopamine replacement therapy for off periods in Parkinson's disease, holds significant market potential due to its ability to provide rapid relief from motor ...
Syndeio Biosciences launches with molecules to target the synapse
Company’s lead candidate is already in a Phase 2 trial for major depressive disorder
What Is A “Dopamine Menu?” It’s Your Time To Welcome Happier Days Ahead
The internet is raving about a new self-care trend that promises to lift your spirits and bring joy to your everyday life. Backed by both creators and mental health experts, it’s a fresh, feel-good approach to emotional well-being—and it might just become your new favorite ritual.
California City Approves Grant to Support Neurotech Startup
The Bakersfield City Council approved a $250,000 grant for a United Kingdom-based neuroscience startup that local educators and business leaders hope will bring high-paying jobs to the area.